bi 1356225
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 9, 2019 (NCT04065295)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Ghrelin O-acyltransferaseINHIBITOR
MBOAT4 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06628622 | Phase 1 | Nov 12, 2024 | Boehringer Ingelheim |
| NCT04447261 | Phase 1 | Jun 30, 2020 | Boehringer Ingelheim |
| NCT04065295 | Phase 1 | Sep 9, 2019 | Boehringer Ingelheim |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 3 | 3 | 1 | 2019 |
1 organizations
Page 1 / 1